INTELLIGENT BIO SOLUTIONS INC
For the period ended Dec 31, 2023. Filed Feb 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2023 · Filed Feb 9, 2024
INBS$2.29+16.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Shareholders’ Equity
| Convertible · Additional · Other · Non- · Total | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| preferred stock · Common stock · Treasury stock · paid in · Accumulated · comprehensive · controlling · shareholders’ | |||||||||||||
| Shares · Amount · Shares · Amount · Shares · Amount · capital · deficit · loss · interest · equity | |||||||||||||
| Balance, June 30, 2023* | - | $ | - | 194,200 | $1,942 | (116) | $(1) | $46,180,112 | $(41,807,573) | $(575,496) | $(111,986) | $3,686,998 | |
| Foreign currency translation loss | - | - | - | - | - | - | - | - | (18,016) | - | (18,016) | ||
| Net loss | - | - | - | - | - | - | - | (2,425,204) | - | (7,220) | (2,432,424) | ||
| Balance, September 30, 2023 | - | - | 194,200 | 1,942 | (116) | (1) | 46,180,112 | (44,232,777) | (593,512) | (119,206) | 1,236,558 | ||
| Issuance of common stock, Series E Preferred Stock and warrants, net of issuance costs | 5,728,723 | 57,287 | 186,018 | 1,860 | - | - | 3,727,017 | - | - | - | 3,786,164 | ||
| Conversion of convertible preferred shares into common stock | (5,728,723) | (57,287) | 477,394 | 4,774 | - | - | 52,513 | - | - | - | - | ||
| Conversion of holdback Series C Preferred Stock into common stock | - | - | 6,248 | 62 | - | - | 32,700 | - | - | - | 32,762 | ||
| Issuance of common stock upon cashless exercise Series F warrants | - | - | 612,182 | 6,122 | - | - | (6,122) | - | - | - | - | ||
| Foreign currency translation gain | - | - | - | - | - | - | - | - | 75,133 | - | 75,133 | ||
| Net loss | - | - | - | - | - | - | - | (1,969,641) | - | (6,742) | (1,976,383) | ||
| Balance, December 31, 2023 | - | $ | - | 1,476,042 | $14,760 | (116) | $(1) | $49,986,220 | $(46,202,418) | $(518,379) | $(125,948) | $3,154,234 | |
| Balance, June 30, 2022* | - | $ | - | 62,042 | $620 | - | $ | - | $38,588,290 | $(31,175,853) | $(788,135) | $(79,151) | $6,545,771 |
| Foreign currency translation loss | - | - | - | - | - | - | - | - | (135,559) | - | (135,559) | ||
| Net loss | - | - | - | - | - | - | - | (1,208,293) | - | (5,785) | (1,214,078) | ||
| Balance, September 30, 2022 | - | - | 62,042 | 620 | - | - | 38,588,290 | (32,384,146) | (923,694) | (84,936) | 5,196,134 | ||
| Issuance of Series C Preferred Stock and common stock for acquisition, net of issuance costs | 2,363,003 | 23,630 | 12,347 | 124 | - | - | 4,700,517 | - | - | - | 4,724,271 | ||
| Issuance of Series D Preferred Stock, net of issuance costs | 176,462 | 1,765 | - | - | - | - | 160,695 | - | - | - | 162,460 | ||
| Stock awards issued to employees | - | - | 2,084 | 21 | - | - | 259,979 | - | - | - | 260,000 | ||
| Payment of tax withholding for employee stock awards | - | - | - | (116) | (1) | (14,406) | - | - | - | (14,407) | |||
| Foreign currency translation gain | - | - | - | - | - | - | - | - | 361,597 | - | 361,597 | ||
| Net loss | - | - | - | - | - | - | - | (420,600) | - | (6,471) | (427,071) | ||
| Balance, December 31, 2022 | 2,539,465 | $25,395 | 76,473 | $765 | (116) | $(1) | $43,695,075 | $(32,804,746) | $(562,097) | $(91,407) | $10,262,984 | ||
| * | Common stock and per share amount have been retroactively adjusted to reflect the decreased number of shares resulting from a 1-for-12 reverse stock split effected on January 26, 2024, and a 1-for-20 reverse stock split effected on February 9, 2023, throughout the condensed consolidated financial statement unless otherwise stated. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.